<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4735780</article-id><article-id pub-id-type="doi">10.1002/cam4.595</article-id><article-id pub-id-type="publisher-id">CAM4595</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical Cancer Research</subject><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma</article-title></title-group><contrib-group><contrib id="cam4595-cr-0001" contrib-type="author"><name><surname>Koole</surname><given-names>Koos</given-names></name><xref ref-type="aff" rid="cam4595-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="cam4595-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cam4595-cr-0002" contrib-type="author"><name><surname>van Kempen</surname><given-names>Pauline M. W.</given-names></name><xref ref-type="aff" rid="cam4595-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cam4595-cr-0003" contrib-type="author"><name><surname>Swartz</surname><given-names>Justin E.</given-names></name><xref ref-type="aff" rid="cam4595-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cam4595-cr-0004" contrib-type="author"><name><surname>Peeters</surname><given-names>Ton</given-names></name><xref ref-type="aff" rid="cam4595-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cam4595-cr-0005" contrib-type="author"><name><surname>van Diest</surname><given-names>Paul J.</given-names></name><xref ref-type="aff" rid="cam4595-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cam4595-cr-0006" contrib-type="author"><name><surname>Koole</surname><given-names>Ron</given-names></name><xref ref-type="aff" rid="cam4595-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cam4595-cr-0007" contrib-type="author"><name><surname>van Es</surname><given-names>Robert J. J.</given-names></name><xref ref-type="aff" rid="cam4595-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cam4595-cr-0008" contrib-type="author" corresp="yes"><name><surname>Willems</surname><given-names>Stefan M.</given-names></name><xref ref-type="aff" rid="cam4595-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="cam4595-aff-0004">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="cam4595-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Pathology</named-content><institution>University Medical Center Utrecht</institution><named-content content-type="street">Heidelberglaan 100</named-content><named-content content-type="country-part">3584 CX</named-content><named-content content-type="city">Utrecht</named-content><country country="NL">The Netherlands</country></aff><aff id="cam4595-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Head and Neck Surgical Oncology</named-content><named-content content-type="organisation-division">UMC Utrecht Cancer Center</named-content><institution>University Medical Center Utrecht</institution><named-content content-type="street">Heidelberglaan 100</named-content><named-content content-type="post-code">3584 CX</named-content><named-content content-type="city">Utrecht</named-content><country country="NL">The Netherlands</country></aff><aff id="cam4595-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Otorhinolaryngology &#x02013; Head and Neck Surgery</named-content><institution>University Medical Center Utrecht</institution><named-content content-type="street">Heidelberglaan 100</named-content><named-content content-type="post-code">3584 CX</named-content><named-content content-type="city">Utrecht</named-content><country country="NL">The Netherlands</country></aff><aff id="cam4595-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Molecular Carcinogenesis</named-content><institution>Netherlands Cancer Institute</institution><named-content content-type="street">Plesmanlaan 121</named-content><named-content content-type="post-code">1066 CX</named-content><named-content content-type="city">Amsterdam</named-content><country country="NL">The Netherlands</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Stefan Willems, Department of Pathology<bold>,</bold> University Medical Center Utrecht, H4.2.41<bold>,</bold> Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Tel: +31 (0) 88 755 6568; Fax: +31 (0) 88 756 9593; E&#x02010;mail: <email>s.m.willems-4@umcutrecht.nl</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2016</year></pub-date><volume>5</volume><issue>2</issue><issue-id pub-id-type="doi">10.1002/cam4.2016.5.issue-2</issue-id><fpage>275</fpage><lpage>284</lpage><history><date date-type="received"><day>07</day><month>8</month><year>2015</year></date><date date-type="rev-recd"><day>06</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>28</day><month>10</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 Published by John Wiley & Sons Ltd. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. <italic>Cancer Medicine</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAM4-5-275.pdf"/><abstract abstract-type="main" id="cam4595-abs-0001"><title>Abstract</title><p>Fibroblast growth factor receptor 3 (<styled-content style="fixed-case">FGFR</styled-content>3) is a member of the fibroblast growth factor receptor tyrosine kinase family. It has been identified as a promising therapeutic target in multiple types of cancer. We have investigated <styled-content style="fixed-case">FGFR</styled-content>3 protein expression and <italic><styled-content style="fixed-case">FGFR</styled-content>3</italic> gene copy&#x02010;numbers in a single well&#x02010;documented cohort of oral and oropharyngeal squamous cell carcinoma. Tissue microarray sets containing 452 formalin&#x02010;fixed paraffin&#x02010;embedded tissues were immunohistochemically stained with an anti&#x02010;<styled-content style="fixed-case">FGFR</styled-content>3 antibody and hybridized with a <italic><styled-content style="fixed-case">FGFR</styled-content>3</italic> fluorescence in situ hybridization probe. <styled-content style="fixed-case">FGFR</styled-content>3 protein expression was correlated with clinicopathological and survival data, which were retrieved from electronic medical records. <styled-content style="fixed-case">FGFR</styled-content>3 <styled-content style="fixed-case">mRNA</styled-content> data of 522 head and neck squamous cell carcinoma (<styled-content style="fixed-case">HNSCC</styled-content>) were retrieved from The Cancer Genome Atlas (<styled-content style="fixed-case">TCGA</styled-content>). Fibroblast growth factor receptor 3 (<styled-content style="fixed-case">FGFR</styled-content>3) protein was overexpressed in 48% (89/185) of oral and 59% (124/211) of oropharyngeal squamous cell carcinoma. Overexpression of <styled-content style="fixed-case">FGFR</styled-content>3 protein was not related to overall survival or disease&#x02010;free survival in oral (<styled-content style="fixed-case">HR</styled-content>[hazard ratio]: 0.94; 95% <styled-content style="fixed-case">CI</styled-content>: 0.64&#x02013;1.39; <italic>P</italic>&#x000a0;=&#x000a0;0.77, <styled-content style="fixed-case">HR</styled-content>: 0.94; 95% <styled-content style="fixed-case">CI</styled-content>: 0.65&#x02013;1.36; <italic>P</italic>&#x000a0;=&#x000a0;0.75) and oropharyngeal squamous cell carcinoma (<styled-content style="fixed-case">HR</styled-content>: 1.21; 95% <styled-content style="fixed-case">CI</styled-content>: 0.81&#x02013;1.80; <italic>P</italic>&#x000a0;=&#x000a0;0.36, <styled-content style="fixed-case">HR</styled-content>: 0.42; 95% <styled-content style="fixed-case">CI</styled-content>: 0.79&#x02013;1.77; <italic>P</italic>&#x000a0;=&#x000a0;0.42). <styled-content style="fixed-case">FGFR</styled-content>3 <styled-content style="fixed-case">mRNA</styled-content> was upregulated in 3% (18/522) of <styled-content style="fixed-case">HNSCC</styled-content> from the <styled-content style="fixed-case">TCGA</styled-content>. The <italic><styled-content style="fixed-case">FGFR</styled-content>3</italic> gene was gained in 0.6% (1/179) of oral squamous cell carcinoma but no amplification was found in oral and oropharyngeal squamous cell carcinoma. In conclusion, <styled-content style="fixed-case">FGFR</styled-content>3 protein is frequently overexpressed in oral and oropharyngeal squamous cell carcinoma. Therefore, it may serve as a potential therapeutic target for <styled-content style="fixed-case">FGFR</styled-content>3&#x02010;directed therapies in oral and oropharyngeal squamous cell carcinoma.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cam4595-kwd-0001">fibroblast growth factor receptor 3</kwd><kwd id="cam4595-kwd-0002">oral cancer</kwd><kwd id="cam4595-kwd-0003">oropharyngeal cancer</kwd><kwd id="cam4595-kwd-0004">therapeutic target</kwd></kwd-group><funding-group><award-group><funding-source>Dutch Cancer Society</funding-source><award-id>2011&#x02013;4964</award-id></award-group></funding-group><counts><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>cam4595</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.6 mode:remove_FC converted:02.02.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cam4595-cit-1001">
<source>Cancer Medicine</source>
<year>2016</year>; <volume>5</volume>(<issue>2</issue>): <fpage>275</fpage>&#x02013;<lpage>284</lpage>
</mixed-citation>
</p></notes></front><body><sec id="cam4595-sec-0001"><title>Introduction</title><p>Fibroblast growth factor receptor 3 (FGFR3) is a cell membrane&#x02010;bound tyrosine kinase receptor belonging to the fibroblast growth factor receptor family (FGFR1&#x02010;4) <xref rid="cam4595-bib-0001" ref-type="ref">1</xref>. Upon binding of specific FGF ligands, the receptor is phosphorylated and multiple downstream signaling pathways are activated. Among these pathways are the mitogen&#x02010;activated protein kinase (MAPK), (phosphoinositide 3&#x02010;kinase/protein kinase B (PI3K/AKT), phosphoinositide phospholipase C (PLC<italic>&#x003b3;</italic>) and signal transducer and activator of transcription (STAT) signaling pathways <xref rid="cam4595-bib-0002" ref-type="ref">2</xref>. Activation of these pathways leads to cell proliferation, migration, invasion, cell survival, and angiogenesis. In cancer, oncogenic aberrations of the <italic>FGFR3</italic> gene cause sustained cell proliferation, contributing to tumor development <xref rid="cam4595-bib-0003" ref-type="ref">3</xref>. Genomic aberrations include <italic>FGFR3</italic> driver mutations, <italic>FGFR3</italic> gene amplification, and <italic>FGFR3</italic> translocations, which frequently occur in bladder cancer, myeloma, and glioblastoma <xref rid="cam4595-bib-0004" ref-type="ref">4</xref>, <xref rid="cam4595-bib-0005" ref-type="ref">5</xref>. Due to its contribution to tumor development, FGFR3 is an interesting therapeutic target and targeted therapies aimed at FGFR3 are emerging. Inhibiting FGFR3 protein with FGFR3&#x02010;directed therapies caused remarkable antitumor effects in preclinical models on brain cancer, colorectal cancer, and multiple myeloma, as well as in clinical trials on glioblastoma patients with tumors bearing <italic>FGFR3&#x02010;TACC3</italic> fusions <xref rid="cam4595-bib-0003" ref-type="ref">3</xref>, <xref rid="cam4595-bib-0004" ref-type="ref">4</xref>, <xref rid="cam4595-bib-0006" ref-type="ref">6</xref>. At the moment, early phase clinical trials are conducted with FGFR3&#x02010;directed targeted therapies on patients with <italic>FGFR3</italic>&#x02010;aberrated glioblastoma multiforme, transitional cell carcinoma, multiple myeloma, and other advanced solid malignancies (ClinicalTrials.gov Identifier: NCT01975701, NCT02278978, NCT02401542, NCT02052778).</p><p>For head and neck squamous cell carcinoma (HNSCC), the knowledge on FGFR3 protein expression is yet limited, while such novel therapeutic targets are highly awaited for disseminated or recurrent HNSCC because current treatment regimens are often ineffective and overall survival rates have remained poor over the past two decades <xref rid="cam4595-bib-0007" ref-type="ref">7</xref>, <xref rid="cam4595-bib-0008" ref-type="ref">8</xref>. In this study, we therefore investigated FGFR3 protein expression and its relation to overall survival, disease&#x02010;free survival, and regional lymph node metastases in well&#x02010;documented cohorts of oral and oropharyngeal squamous cell carcinoma (OSCC, OPSCC). Second, we investigated <italic>FGFR3</italic> gene copy&#x02010;numbers in these OSCC and OPSCC cohorts.</p></sec><sec id="cam4595-sec-0002"><title>Materials and Methods</title><sec id="cam4595-sec-0003"><title>Patient cohort</title><p>The inclusion criteria were as follows: patients with a first primary OPSCC or OSCC who were treated at the University Medical Center Utrecht (UMC Utrecht) between&#x000a0;August 1996 and December 2011. The exclusion criteria were as follows: a previous history of HNSCC, a synchronous primary tumor, histologic abnormalities including inflammation and dysplastic lesions, and the absence of tumor cores on tissue microarray (TMA) slides. The patient cohort included 212 OSCC and 240 OPSCC patients. TMA cores were absent for 27 OSCC and 29 OPSCC, leaving 185 OSCC and 211 OPSCC for analysis of FGFR3 protein expression. OSCC and OPSCC patients were treated according to the Dutch National Guideline for Head and Neck Cancer 2014 <xref rid="cam4595-bib-0009" ref-type="ref">9</xref>. The treatment regimen of OSCC consisted of primary surgical resection and an additional neck dissection and/or postoperative radiotherapy or chemoradiotherapy if recommended. The treatment regimen of OPSCC consisted of primary surgery, radiotherapy, or chemoradiotherapy and an additional neck dissection or postoperative radiotherapy or chemoradiotherapy if recommended. For OSCC patients, the median follow&#x02010;up of overall survival was 90.5&#x000a0;months and of disease&#x02010;free survival was 91.5&#x000a0;months. For OPSCC patients, the median follow&#x02010;up time of overall survival was 71&#x000a0;months and of disease&#x02010;free survival was 63&#x000a0;months. Clinicopathological patient and tumor characteristics were retrieved from electronic medical records and formalin&#x02010;fixed paraffin&#x02010;embedded tissues of all tumors were collected. Oral squamous cell carcinoma (OSCC) tissues were surgical resection specimens as surgery was the standard treatment regimen for OSCC, and OPSCC tissues were mainly pretreatment biopsy specimens as chemoirradiation was the treatment regimen for the majority of OPSCC. Since limited OPSCC resection specimens were available for microscopic analysis by a pathologist, pathological characteristics of these tumors were not available. The Human Papillomavirus (HPV) status of all tumors was determined by P16 immunohistochemistry and linear array, as described previously <xref rid="cam4595-bib-0010" ref-type="ref">10</xref>. &#x0201c;The code for proper secondary use of human tissue&#x0201d; and &#x0201c;The code of conduct for the use of data in health research&#x0201d; of the Federation of Dutch Medical Scientific Societies were followed when handling human tissues and patient data (Federa FMVV, updated 2011).</p></sec><sec id="cam4595-sec-0004"><title>Tissue microarray construction</title><p>Slides (4&#x000a0;<italic>&#x003bc;</italic>m) cut from formalin&#x02010;fixed paraffin&#x02010;embedded (FFPE) tissue blocks were hematoxylin stained and tumor areas were marked by a dedicated head and neck pathologist (SMW). Three 0.6&#x000a0;mm cores were punched from marked tumor areas of each FFPE tissue block and these were arrayed into recipient paraffin donor blocks using a TMA Grand Master (3DHISTECH, Budapest, Hungary). Six normal oral and tonsillar tissue TMA cores were arrayed in each TMA and served as staining quality controls.</p></sec><sec id="cam4595-sec-0005"><title>Immunohistochemistry</title><p>Tissue microarray (TMA) slides were immunohistochemically stained using a mouse monoclonal anti&#x02010;FGFR3 (B&#x02010;9) SC&#x02010;13121 antibody (Santa Cruz Biotechnology, Dallas, TX). The anti&#x02010;FGFR3 antibody was tested for the following tissue pretreatments; EDTA, citrate, pepsine and no treatment, and the following antibody dilutions; 1:10, 1:25, 1:50, 1:100, 1:250, 1:500, and 1:1000 on a positive control (normal liver tissue) and negative control (normal stomach tissue) to verify the antibody's specificity for FGFR3 protein <xref rid="cam4595-bib-0011" ref-type="ref">11</xref>. Tissue pretreatment with EDTA and a 1:25 antibody dilution showed the most specific staining. The following manual staining protocol was used; first, TMA slides were deparaffinized and treated with peroxidase inhibitor for 15&#x000a0;min, followed by an EDTA pretreatment step at 100&#x000b0;C for 20&#x000a0;min. After rinsing in demineralized water and PBS tween, slides were incubated with primary anti&#x02010;FGFR3 antibody at 1:25 dilution for one hour and rinsed in PBS sequenza. Next, slides were incubated with 150&#x000a0;<italic>&#x003bc;</italic>L poly&#x02010;HRP&#x02010;anti&#x02010;mouse/rabbit/rat IgG secondary antibody (Immunologic, Duiven, The Netherlands) for 30&#x000a0;min, followed by rinsing in PBS sequenza and citrate buffer. 200&#x000a0;<italic>&#x003bc;</italic>L 3,3&#x02019;&#x02010;diaminobenzidine (DAB) was applied for 10&#x000a0;min and slides were rinsed in citrate buffer. Finally, slides were counterstained with hematoxylin, dehydrated, and covered.</p><p>To quantify FGFR3 protein expression, the resultant immunohistochemical stain was scored in a semiquantitative manner by two observers (S. M. W and K. K) blinded to patient's outcome. The percentage of positively stained tumor cells was scored and the mean tumor cell percentage was computed from available TMA cores for each tumor. Seventy&#x02010;four tumors included in the analysis had only one TMA core available and 138 tumors had only two. Continuous tumor cell percentage scores were dichotomized by a cut&#x02010;off value, which was optimized to best predicting patient overall survival using log&#x02010;likelihood values <xref rid="cam4595-bib-0012" ref-type="ref">12</xref>. A cut&#x02010;off value of 33% was selected for both OSCC and OPSCC. The staining intensity was not scored because it was homogenous among all TMA cores.</p></sec><sec id="cam4595-sec-0006"><title>Fluorescence in situ hybridization</title><p>Tissue microarrays were hybridized with an <italic>IGH/FGFR3</italic> (<italic>IGH</italic>, immunoglobulin heavy locus) translocation dual fusion FISH (fluorescence in situ hybridization) probe (Cytocell, Cambridge, UK). In brief, 4&#x000a0;<italic>&#x003bc;</italic>m TMA slides were deparaffinized, rinsed in HCL solution, and pretreated with citrate and protease buffer. Next, these slides were dehydrated, and incubated with 15&#x000a0;<italic>&#x003bc;</italic>L Fluorescence in situ hybridization (FISH) probe for 5&#x000a0;min at 78&#x000b0;C. After cooling samples for 5&#x000a0;min, TMA slides were incubated overnight at 37&#x000b0;C in a Thermobrite (Abbott Laboratories, Abbott Park, IL). The next day, TMA slides were rinsed in specific saline&#x02010;sodium citrate buffers and counterstained with 4&#x02019;,6&#x02010;diamidino&#x02010;2&#x02010;phenylindole (DAPI). Finally, slides were dehydrated and 15&#x000a0;<italic>&#x003bc;</italic>L vectashield was applied. To determine <italic>FGFR3</italic> gene copy&#x02010;numbers, 50 tumor cell nuclei per tumor were assessed on <italic>FGFR3</italic> and <italic>IGH</italic> gene copy&#x02010;numbers at 100&#x000d7; magnification using a Leica DM5500 B microscope system with Leica application suite advanced fluorescence software (Leica Microsystems, Rijswijk, The Netherlands). A <italic>FGFR3/IGH</italic> ratio was calculated and defined as: &#x0003c;1.5: normal copy&#x02010;numbers, 1.5&#x02013;2.0: copy&#x02010;number gain and &#x0003e;2.0: gene amplification <xref rid="cam4595-bib-0013" ref-type="ref">13</xref>.</p></sec><sec id="cam4595-sec-0007"><title>TCGA data collection</title><p>FGFR3 mRNA data, available for 522 HNSCC, were retrieved from The Cancer Genome Atlas (TCGA) Research Network (<ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>). Data were extracted from the TCGA Head and Neck Squamous Cell Carcinoma Provisional study through the cBioPortal for Cancer Genomics website (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/">http://www.cbioportal.org/</ext-link>) on the 29th of September, 2015 <xref rid="cam4595-bib-0014" ref-type="ref">14</xref>, <xref rid="cam4595-bib-0015" ref-type="ref">15</xref>. Upregulated FGFR3 mRNA levels were defined as z&#x02010;scores above two standard deviations and downregulated FGFR3 mRNA levels as below two standard deviations from the reference population. No limitations or publication restrictions were laid upon the HNSCC data, as stated by the TCGA publication guidelines.</p></sec><sec id="cam4595-sec-0008"><title>Statistical analysis</title><p>Statistical analysis was performed using IBM SPSS Statistics software, version 22 (IBM, Amonk, NY). Pearson's chi square test was used for dichotomous variables or Fisher's exact test for the variables; primary treatment type, neck dissection and HPV status, and <italic>t</italic>&#x02010;test was used for continuous variables to compare baseline characteristics between OSCC and OPSCC. A Pearson's chi square test was used to compare protein expression between OSCC and OPSCC. A Pearson's chi square was also used to analyze univariate associations between FGFR3 protein expression and clinicopathological variables.</p><p>Only patients who were treated with curative intent were included in the survival analysis. The median follow&#x02010;up time was estimated using the reverse Kaplan&#x02013;Meier method. The relation between FGFR3 protein expression and both overall survival and disease&#x02010;free survival was analyzed by plotting Kaplan&#x02013;Meier survival curves and comparing them by log&#x02010;rank test. Associations were further analyzed by univariate Cox regression. Two&#x02010;sided <italic>P</italic>&#x02010;values below 0.05 were considered significant throughout all statistical computations.</p></sec></sec><sec id="cam4595-sec-0009"><title>Results</title><sec id="cam4595-sec-0010"><title>Clinicopathological characteristics</title><p>The OSCC patient cohort included 212 OSCC, of which 30% were early I&#x02013;II stage tumors and 70% advanced III&#x02013;IV stage tumors (Table&#x000a0;<xref rid="cam4595-tbl-0001" ref-type="table-wrap">1</xref>). Regarding treatment regimens, all OSCC were primarily treated with surgery (100%) and 97% received a neck dissection. Postoperative radiotherapy was administered to the primary site and/or neck in 34%. The OPSCC patient cohort included 240 OPSCC, of which 15% were early I&#x02013;II stage tumors and 85% advanced III&#x02013;IV stage tumors. 19% of OPSCC were HPV&#x02010;positive and 81% HPV&#x02010;negative. HPV status was missing for nine OPSCC. Of all OPSCC's, 77% were treated either primarily or postoperative with chemo&#x02010;irradiation or radiotherapy. Twenty&#x02010;five percent were primarily treated with surgery. Eleven percent of OPSCC were treated with palliative intent.</p><table-wrap id="cam4595-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinicopathological characteristics of oral and oropharyngeal squamous cell carcinoma cohorts</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Clinicopathological characteristics</th><th align="left" valign="top" rowspan="1" colspan="1">OSCC <italic>n</italic> (%)</th><th align="left" valign="top" rowspan="1" colspan="1">OPSCC <italic>n</italic> (%)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total number of cases</td><td align="left" rowspan="1" colspan="1">212 (100)</td><td align="left" rowspan="1" colspan="1">240 (100)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Age</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (range)</td><td align="left" rowspan="1" colspan="1">62 (26&#x02013;87)</td><td align="left" rowspan="1" colspan="1">59 (35&#x02013;88)</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" colspan="4" rowspan="1">Sex</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">128 (60)</td><td align="left" rowspan="1" colspan="1">167 (70)</td><td align="left" rowspan="1" colspan="1">0.040</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">84 (40)</td><td align="left" rowspan="1" colspan="1">73 (30)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Tobacco smoking</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Never</td><td align="left" rowspan="1" colspan="1">77 (36)</td><td align="left" rowspan="1" colspan="1">48 (20)</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">133 (63)</td><td align="left" rowspan="1" colspan="1">192 (80)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">2 (1)</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Alcohol consumption</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Never</td><td align="left" rowspan="1" colspan="1">102 (48)</td><td align="left" rowspan="1" colspan="1">38 (15.5)</td><td align="left" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">108 (51)</td><td align="left" rowspan="1" colspan="1">201 (84)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">2 (1)</td><td align="left" rowspan="1" colspan="1">1 (0.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Clinical T&#x02010;stage</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">cT1</td><td align="left" rowspan="1" colspan="1">44 (21)</td><td align="left" rowspan="1" colspan="1">21 (8.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">cT2</td><td align="left" rowspan="1" colspan="1">79 (37)</td><td align="left" rowspan="1" colspan="1">68 (28)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">cT3</td><td align="left" rowspan="1" colspan="1">19 (9)</td><td align="left" rowspan="1" colspan="1">56 (23)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">cT4</td><td align="left" rowspan="1" colspan="1">70 (33)</td><td align="left" rowspan="1" colspan="1">94 (39)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">1 (0.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Clinical N&#x02010;stage</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">cN0</td><td align="left" rowspan="1" colspan="1">146 (69)</td><td align="left" rowspan="1" colspan="1">60 (25)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">cN1&#x02010;3</td><td align="left" rowspan="1" colspan="1">66 (31)</td><td align="left" rowspan="1" colspan="1">175 (74)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">3 (1)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Pathological N&#x02010;stage</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">pN0</td><td align="left" rowspan="1" colspan="1">91 (43)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">pN1&#x02010;3</td><td align="left" rowspan="1" colspan="1">114 (54)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">7 (3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Tumor stage</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Early I&#x02013;II</td><td align="left" rowspan="1" colspan="1">64 (30)</td><td align="left" rowspan="1" colspan="1">36 (15)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Advanced III&#x02013;IV</td><td align="left" rowspan="1" colspan="1">148 (70)</td><td align="left" rowspan="1" colspan="1">204 (85)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Primary treatment type</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Surgery</td><td align="left" rowspan="1" colspan="1">212 (100)</td><td align="left" rowspan="1" colspan="1">61 (25)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Radiotherapy or chemoradiotherapy</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">153 (64)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Palliative</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">26 (11)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Neck dissection</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">205 (97)</td><td align="left" rowspan="1" colspan="1">28 (12)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">7 (3)</td><td align="left" rowspan="1" colspan="1">186 (77)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Palliative</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">26 (11)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Postoperative Radiotherapy or chemoradiotherapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">73 (34)</td><td align="left" rowspan="1" colspan="1">31 (13)</td><td align="left" rowspan="1" colspan="1">0.020</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">139 (66)</td><td align="left" rowspan="1" colspan="1">30 (13)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Palliative</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">26 (11)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Extra nodal growth</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No or pN0</td><td align="left" rowspan="1" colspan="1">154 (73)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">56 (26)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">2 (1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Vaso&#x02010;invasion</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">169 (80)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">39 (18)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">4 (2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Perineural growth</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">122 (58)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">80 (38)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">10 (4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Bone invasion</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">152 (72)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">60 (28)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Growth pattern</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cohesive</td><td align="left" rowspan="1" colspan="1">44 (20.5)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Noncohesive</td><td align="left" rowspan="1" colspan="1">167 (79)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">1 (0.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Infiltration depth</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">0&#x02013;4&#x000a0;mm</td><td align="left" rowspan="1" colspan="1">19 (9)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003e;4&#x000a0;mm</td><td align="left" rowspan="1" colspan="1">193 (91)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Differentiation grade</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Well/moderate</td><td align="left" rowspan="1" colspan="1">173 (82)</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Poor/undifferentiated</td><td align="left" rowspan="1" colspan="1">39 (18)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">HPV&#x02010;16</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">2 (1)</td><td align="left" rowspan="1" colspan="1">43 (18)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">210 (99)</td><td align="left" rowspan="1" colspan="1">188 (78)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing</td><td align="left" rowspan="1" colspan="1">0 (0)</td><td align="left" rowspan="1" colspan="1">9 (4)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="cam4595-note-0002"><p>OSCC, oral squamous cell carcinoma; OPSCC, oropharyngeal squamous cell carcinoma.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="cam4595-sec-0011"><title>FGFR3 protein is frequently overexpressed in oral and oropharyngeal squamous cell carcinoma</title><p>Representative microscopic images of FGFR3 protein expression are shown in Figure<bold>&#x000a0;</bold>
<xref rid="cam4595-fig-0001" ref-type="fig">1</xref>. A subset of OSCC and OPSCC showed more intense staining and a subset showed lighter staining compared to the faint staining observed in normal oral and tonsillar tissue. Specifically, FGFR3 protein was overexpressed in 48% (89/185) of OSCC and 59% (124/211) of OPSCC (Fig.&#x000a0;<xref rid="cam4595-fig-0002" ref-type="fig">2</xref>A, Table&#x000a0;<xref rid="cam4595-tbl-0001" ref-type="table-wrap">1</xref>). FGFR3 protein expression was unknown for 27 OSCC and 29 OPSCC because all three TMA cores of the tumor were missing. Overexpression of FGFR3 protein occurred significantly more in OPSCC (<italic>P</italic>&#x000a0;=&#x000a0;0.034). Regarding the OPSCC population, there was no significant difference in FGFR3 protein expression between HPV&#x02010;positive and &#x02010;negative OPSCC (<italic>P</italic>&#x000a0;=&#x000a0;0.489). To investigate the underlying mechanism of FGFR3 protein overexpression in OSCC and OPSCC, FGFR3 mRNA data of 522 HNSCC were retrieved from The Cancer Genome Atlas (TCGA) Research Network. FGFR3 mRNA levels were upregulated in 3% (18/522) of HNSCC and normal in the rest of the HNSCC cohort (Fig.&#x000a0;<xref rid="cam4595-fig-0002" ref-type="fig">2</xref>B). None of them showed downregulated FGFR3 mRNA levels. In the OSCC and OPSCC cohort, the <italic>FGFR3</italic> gene was gained in only 0.6% (1/179) of OSCC, but not truly amplified in OSCC nor OPSCC (Fig.&#x000a0;<xref rid="cam4595-fig-0001" ref-type="fig">1</xref>, Table S1).</p><fig fig-type="Figure" xml:lang="en" id="cam4595-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Microscopic images of immunohistochemical staining for <styled-content style="fixed-case">FGFR</styled-content>3 protein at 10&#x000d7; and 40&#x000d7; magnification and fluorescence in situ hybridization of the <italic><styled-content style="fixed-case">FGFR</styled-content>3</italic> gene at 100&#x000d7; magnification. Tissue microarray slides containing oral and oropharyngeal squamous cell carcinoma cores (0.6&#x000a0;mm) were immunohistochemically stained for <styled-content style="fixed-case">FGFR</styled-content>3 protein using an anti&#x02010;<styled-content style="fixed-case">FGFR</styled-content>3 antibody. Fluorescence in situ hybridization of the <italic><styled-content style="fixed-case">FGFR</styled-content>3</italic> gene was performed on another set of tissue microarray slides. Strong immunohistochemical staining was observed in (A) oral squamous cell carcinoma and (B) oropharyngeal squamous cell carcinoma overexpressing <styled-content style="fixed-case">FGFR</styled-content>3 protein. No staining was observed in (C) oral squamous cell carcinoma and (D) oropharyngeal squamous cell carcinoma not expressing <styled-content style="fixed-case">FGFR</styled-content>3 protein. Normal tonsillar tissue (E) showed no staining for <styled-content style="fixed-case">FGFR</styled-content>3 protein. (F) <italic><styled-content style="fixed-case">FGFR</styled-content>3</italic> copy&#x02010;number gain and (G) normal <italic><styled-content style="fixed-case">FGFR</styled-content>3</italic> gene copy&#x02010;numbers in oral squamous cell carcinoma. The red probe signal is hybridized to the <italic><styled-content style="fixed-case">FGFR</styled-content>3</italic> gene and the green probe signal is hybridized to the <italic><styled-content style="fixed-case">IGH</styled-content></italic> gene. <styled-content style="fixed-case">FGFR</styled-content>3, fibroblast growth factor receptor 3; <styled-content style="fixed-case">OPSCC</styled-content>, oropharyngeal squamous cell carcinoma; <styled-content style="fixed-case">OSCC</styled-content>, oral squamous cell carcinoma; <italic>IGH</italic>, immunoglobulin heavy locus.</p></caption><graphic id="nlm-graphic-3" xlink:href="CAM4-5-275-g001"/></fig><fig fig-type="Figure" xml:lang="en" id="cam4595-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Prevalence of <styled-content style="fixed-case">FGFR</styled-content>3 protein overexpression and <styled-content style="fixed-case">FGFR</styled-content>3 <styled-content style="fixed-case">mRNA</styled-content> levels in head and neck squamous cell carcinoma. (A) Tissue microarray slides containing oral and oropharyngeal squamous cell carcinoma cores (0.6&#x000a0;mm) were immunohistochemically stained for <styled-content style="fixed-case">FGFR</styled-content>3 protein using an anti&#x02010;<styled-content style="fixed-case">FGFR</styled-content>3 antibody. <styled-content style="fixed-case">FGFR</styled-content>3 protein was overexpressed in 48% (89/185) of oral squamous cell carcinoma and 59% (124/211) of oropharyngeal squamous cell carcinoma. Within the oropharyngeal population, <styled-content style="fixed-case">FGFR</styled-content>3 protein was overexpressed in 53% (20/38) of <styled-content style="fixed-case">HPV</styled-content>&#x02010;positive and 59% (97/165) of <styled-content style="fixed-case">HPV</styled-content>&#x02010;negative oropharyngeal squamous cell carcinoma. (B) Data on <styled-content style="fixed-case">FGFR</styled-content>3 <styled-content style="fixed-case">mRNA</styled-content> levels of 522 <styled-content style="fixed-case">HNSCC</styled-content> were retrieved from The Cancer Genome Atlas (<styled-content style="fixed-case">TCGA</styled-content>) Research Network on the 29th of September, 2015. <styled-content style="fixed-case">FGFR</styled-content>3 <styled-content style="fixed-case">mRNA</styled-content> levels were upregulated in 3% (18/522) of all <styled-content style="fixed-case">HNSCC</styled-content> and normal in all other <styled-content style="fixed-case">HNSCC</styled-content> head and neck squamous cell carcinoma. <styled-content style="fixed-case">FGFR</styled-content>3, fibroblast growth factor receptor 3; <styled-content style="fixed-case">HPV</styled-content>, human papillomavirus; <styled-content style="fixed-case">OPSCC</styled-content>, oropharyngeal squamous cell carcinoma; <styled-content style="fixed-case">OSCC</styled-content>, oral squamous cell carcinoma.</p></caption><graphic id="nlm-graphic-5" xlink:href="CAM4-5-275-g002"/></fig></sec><sec id="cam4595-sec-0012"><title>FGFR3 protein expression is not related to overall survival or disease&#x02010;free survival in oral and oropharyngeal squamous cell carcinoma</title><p>Expression of FGFR3 protein was not related to overall survival or disease&#x02010;free survival in OSCC patients (HR [hazard ratio]: 0.94; 95% CI: 0.64&#x02013;1.39; <italic>P</italic>&#x000a0;=&#x000a0;0.769, HR: 0.94; 95% CI: 0.65&#x02013;1.36; <italic>P</italic>&#x000a0;=&#x000a0;0.750). Also not in OPSCC patients (HR: 1.21; 95% CI: 0.81&#x02013;1.80; <italic>P</italic>&#x000a0;=&#x000a0;0.361, HR: 0.42; 95% CI: 0.79&#x02013;1.77; <italic>P</italic>&#x000a0;=&#x000a0;0.419) (Fig.&#x000a0;<xref rid="cam4595-fig-0003" ref-type="fig">3</xref>, Fig. S1). Furthermore, FGFR3 protein expression was not related to overall survival or disease&#x02010;free survival in subgroups of HPV&#x02010;positive OPSCC (HR [hazard ratio]: 0.74; 95% CI: 0.20&#x02013;2.77; <italic>P</italic>&#x000a0;=&#x000a0;0.657, HR: 0.48; 95% CI: 0.14&#x02013;1.64; <italic>P</italic>&#x000a0;=&#x000a0;0.241) and HPV&#x02010;negative OPSCC patients (HR: 1.28; 95% CI: 0.84&#x02013;1.97; <italic>P</italic>&#x000a0;=&#x000a0;0.249, HR: 1.40; 95% CI: 0.90&#x02013;2.16; <italic>P</italic>&#x000a0;=&#x000a0;0.133). Fibroblast growth factor receptor 3 (FGFR3) protein expression showed no relevant relationship with clinicopathological variables, including differentiation grade, tumor stage, and regional lymph node metastases.</p><fig fig-type="Figure" xml:lang="en" id="cam4595-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Kaplan&#x02013;Meier overall survival curves for <styled-content style="fixed-case">FGFR</styled-content>3 protein expression in oral and oropharyngeal squamous cell carcinoma. Tissue microarray slides containing cores (0.6&#x000a0;mm) of 212 oral and 240 oropharyngeal squamous cell carcinoma were immunohistochemically stained for <styled-content style="fixed-case">FGFR</styled-content>3 protein using an anti&#x02010;<styled-content style="fixed-case">FGFR</styled-content>3 antibody. <styled-content style="fixed-case">FGFR</styled-content>3 protein expression was not related to overall survival in (<bold>A</bold>) oral squamous cell carcinoma (<styled-content style="fixed-case">HR</styled-content>: 0.94; 95% <styled-content style="fixed-case">CI</styled-content>: 0.64&#x02013;1.39; <italic>P</italic>&#x000a0;=&#x000a0;0.769) and (B) oropharyngeal squamous cell carcinoma (<styled-content style="fixed-case">HR</styled-content>: 1.21; 95% <styled-content style="fixed-case">CI</styled-content>: 0.81&#x02013;1.80; <italic>P</italic>&#x000a0;=&#x000a0;0.361). Similarly, <styled-content style="fixed-case">FGFR</styled-content>3 protein expression was not related to overall survival in (C) <styled-content style="fixed-case">HPV</styled-content>&#x02010;positive (<styled-content style="fixed-case">HR</styled-content>: 0.74; 95% <styled-content style="fixed-case">CI</styled-content>: 0.20&#x02013;2.77; <italic>P</italic>&#x000a0;=&#x000a0;0.657) and (D) <styled-content style="fixed-case">HPV</styled-content>&#x02010;negative oropharyngeal squamous cell carcinoma (<styled-content style="fixed-case">HR</styled-content>: 1.28; 95% <styled-content style="fixed-case">CI</styled-content>: 0.84&#x02013;1.97; <italic>P</italic>&#x000a0;=&#x000a0;0.249). <styled-content style="fixed-case">FGFR</styled-content>3, fibroblast growth factor receptor 3; HPV, human papillomavirus; HR, hazard ratio.</p></caption><graphic id="nlm-graphic-7" xlink:href="CAM4-5-275-g003"/></fig></sec></sec><sec id="cam4595-sec-0013"><title>Discussion</title><p>In this study, FGFR3 protein appeared to be frequently overexpressed in both OSCC and OPSCC, and FGFR3 mRNA was found to be upregulated in HNSCC from the TCGA Research Network. Upregulated FGFR3 mRNA levels may account for the overexpression of FGFR3 protein in a minor subset of FGFR3&#x02010;overexpressed OSCC and OPSCC samples. However, for the majority of FGFR3&#x02010;overexpressed samples, the mechanism of overexpression remains unknown. Similar overexpression of FGFR3 protein has been observed in a previous study. They observed FGFR3 protein overexpression in 13 of 14 OSCC cell lines and in five OSCC tissues <xref rid="cam4595-bib-0016" ref-type="ref">16</xref>. Their method was Quantitative Reverse Transcription Polymerase Chain Reaction (QRT&#x02010;PCR), whereas immunohistochemistry was used in this study. Since no consensus on a cut&#x02010;off value has been reached yet, we selected an arbitrary cut&#x02010;off value to define protein overexpression by immunohistochemistry. Fibroblast growth factor receptor 3 (FGFR3) protein has become an interesting therapeutic target as several FGFR inhibitor therapies have become available. These FGFR inhibitors show promising therapeutic value for treating HNSCC in in vitro and in vivo experiments. For example, targeting FGFR3 with FGFR&#x02010;inhibitor PD173074 reduced cell proliferation and enhanced radiotherapy sensitivity of resistant OSCC cell lines and xenografts <xref rid="cam4595-bib-0017" ref-type="ref">17</xref>. Hence, targeting FGFR3 could be of interest for radiotherapy treatment strategies in radiotherapy resistant OSCC patients.</p><p>Regarding other types of cancer, the overexpression of FGFR3 protein has been observed in a wide spectrum of solid tumors including transitional cell, hepatocellular, and breast carcinoma, as well as multiple myeloma <xref rid="cam4595-bib-0018" ref-type="ref">18</xref>, <xref rid="cam4595-bib-0019" ref-type="ref">19</xref>, <xref rid="cam4595-bib-0020" ref-type="ref">20</xref>, <xref rid="cam4595-bib-0021" ref-type="ref">21</xref>, <xref rid="cam4595-bib-0022" ref-type="ref">22</xref>, <xref rid="cam4595-bib-0023" ref-type="ref">23</xref>, <xref rid="cam4595-bib-0024" ref-type="ref">24</xref>. Similar overexpression of FGFR3 protein was observed in this study. Though, the contribution of FGFR3 protein overexpression to tumor progression seems to be tumor&#x02010;type dependent. FGFR3 protein overexpression drives tumor progression in bladder cancer, lung cancer, multiple myeloma, and glioblastoma, whereas it prevents tumor progression in cutaneous squamous cell carcinoma <xref rid="cam4595-bib-0025" ref-type="ref">25</xref>, <xref rid="cam4595-bib-0026" ref-type="ref">26</xref>. In HNSCC, FGFR3 protein overexpression seems to drive tumor progression, as reported by Uzawa et&#x000a0;al. <xref rid="cam4595-bib-0017" ref-type="ref">17</xref>.</p><p>We found FGFR3 protein expression to be of no prognostic value in OSCC as well as in OPSCC. The prognostic value of FGFR3 protein expression has not been evaluated before <xref rid="cam4595-bib-0027" ref-type="ref">27</xref>. This holds both true for HPV&#x02010;negative and HPV&#x02010;positive tumors despite their different mechanism of FGFR3 activation. The prognostic value of FGFR3 protein expression seems to be tumor&#x02010;type dependent. Similar to this HNSCC study, FGFR3 protein expression holds no prognostic value in non&#x02010;small cell lung cancer <xref rid="cam4595-bib-0028" ref-type="ref">28</xref>. This is in contrast to multiple myeloma and breast cancer, in which FGFR3 protein expression has been related to poor progression&#x02010;free survival and overall survival <xref rid="cam4595-bib-0023" ref-type="ref">23</xref>, <xref rid="cam4595-bib-0024" ref-type="ref">24</xref>. For transitional cell carcinoma, the prognostic value for FGFR3 expression is still a subject of debate <xref rid="cam4595-bib-0018" ref-type="ref">18</xref>, <xref rid="cam4595-bib-0019" ref-type="ref">19</xref>, <xref rid="cam4595-bib-0029" ref-type="ref">29</xref>, <xref rid="cam4595-bib-0030" ref-type="ref">30</xref>, <xref rid="cam4595-bib-0031" ref-type="ref">31</xref>, <xref rid="cam4595-bib-0032" ref-type="ref">32</xref>, <xref rid="cam4595-bib-0033" ref-type="ref">33</xref>, <xref rid="cam4595-bib-0034" ref-type="ref">34</xref>.</p><p>Previous large&#x02010;scale genomic characterization studies show that the <italic>FGFR3</italic> gene is frequently aberrant in HPV&#x02010;positive HNSCC (11%) and much less in HPV&#x02010;negative HNSCC (2%) <xref rid="cam4595-bib-0035" ref-type="ref">35</xref>, <xref rid="cam4595-bib-0036" ref-type="ref">36</xref>. Specifically, <italic>FGFR3&#x02010;TACC3</italic> translocations occur predominantly in HPV&#x02010;positive HNSCC, whereas <italic>FGFR3</italic> amplification occurs in HPV&#x02010;negative HNSCC and <italic>FGFR3</italic> mutations occur in both. Tumors bearing these <italic>FGFR3</italic> gene aberrations respond very well to FGFR&#x02010;inhibitors in preclinical models and early phase clinical studies <xref rid="cam4595-bib-0037" ref-type="ref">37</xref>. Considering the frequent occurrence of <italic>FGFR3</italic> aberrations in HPV&#x02010;positive HNSCC and impressive response to FGFR&#x02010;inhibitors, FGFR3 protein might be of therapeutic value in this HNSCC subpopulation. Clinical studies are currently focusing on this HPV&#x02010;positive subpopulation <xref rid="cam4595-bib-0037" ref-type="ref">37</xref>. The <italic>FGFR3</italic> amplification observed by the previous study in a mixed HPV&#x02010;negative HNSCC cohort was not observed in the OSCC and OPSCC cohorts in this study <xref rid="cam4595-bib-0030" ref-type="ref">30</xref>. An explanation could be that the <italic>FGFR3</italic> gene is amplified in HNSCC tumors other than OSCC and OPSCC or gene amplification is not detected by our FISH analysis due to the arbitrarily selected ratio and cut&#x02010;off values. In the OSCC and OPSCC of this study, other mechanisms than <italic>FGFR3</italic> gene amplification are probably responsible for FGFR3 protein overexpression.</p><p>In conclusion, FGFR3 protein is frequently overexpressed in both OSCC and OPSCC. Although FGFR3 protein expression is not related to overall survival or disease&#x02010;free survival, previous studies found a high occurrence rate of <italic>FGFR3</italic> genomic aberrations in HNSCC. Therefore, FGFR3 protein may be an interesting therapeutic target for FGFR3&#x02010;directed therapies in OSCC and OPSCC.</p></sec><sec id="cam4595-sec-0014"><title>Conflict of Interest</title><p>All authors had no conflicts of interest to declare.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>
<bold>Figure S1.</bold> Kaplan&#x02013;Meier disease&#x02010;free survival curves for FGFR3 protein expression in oral and oropharyngeal squamous cell carcinoma.</p></caption><media xlink:href="CAM4-5-275-s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data"><caption><p>
<bold>Table S1</bold>. FGFR3 protein expression and <italic>FGFR3</italic> gene copy&#x02010;numbers in oral and oropharyngeal squamous cell carcinoma.</p></caption><media xlink:href="CAM4-5-275-s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="cam4595-bibl-0001"><title>References</title><ref id="cam4595-bib-0001"><label>1</label><mixed-citation publication-type="journal">
<string-name>
<surname>Brooks</surname>, <given-names>A. N.</given-names>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Kilgour</surname>
</string-name>, and <string-name>
<given-names>P. D.</given-names>
<surname>Smith</surname>
</string-name>. <year>2012</year>
<article-title>Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer</article-title>. <source>Clin. Cancer Res.</source>
<volume>18</volume>:<fpage>1855</fpage>&#x02013;<lpage>1862</lpage>.<pub-id pub-id-type="pmid">22388515</pub-id></mixed-citation></ref><ref id="cam4595-bib-0002"><label>2</label><mixed-citation publication-type="journal">
<string-name>
<surname>L'H&#x000f4;te</surname>, <given-names>C. G.</given-names>
</string-name>, and <string-name>
<given-names>M. A.</given-names>
<surname>Knowles</surname>
</string-name>. <year>2005</year>
<article-title>Cell responses to FGFR3 signalling: growth, differentiation and apoptosis</article-title>. <source>Exp. Cell Res.</source>
<volume>304</volume>:<fpage>417</fpage>&#x02013;<lpage>431</lpage>.<pub-id pub-id-type="pmid">15748888</pub-id></mixed-citation></ref><ref id="cam4595-bib-0003"><label>3</label><mixed-citation publication-type="journal">
<string-name>
<surname>Daniele</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Corral</surname>
</string-name>, <string-name>
<given-names>L. R.</given-names>
<surname>Molife</surname>
</string-name>, and <string-name>
<given-names>J. S.</given-names>
<surname>de Bono</surname>
</string-name>. <year>2012</year>
<article-title>FGF receptor inhibitors: role in cancer therapy</article-title>. <source>Curr. Oncol. Rep.</source>
<volume>14</volume>:<fpage>111</fpage>&#x02013;<lpage>119</lpage>.<pub-id pub-id-type="pmid">22311684</pub-id></mixed-citation></ref><ref id="cam4595-bib-0004"><label>4</label><mixed-citation publication-type="journal">
<string-name>
<surname>Dienstmann</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Rodon</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Prat</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Perez&#x02010;Garcia</surname>
</string-name>, <string-name>
<given-names>B.</given-names>&#x000a0;<surname>Adamo</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Felip</surname>
</string-name>, et&#x000a0;al. <year>2014</year>
<article-title>Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors</article-title>. <source>Ann. Oncol.</source>
<volume>25</volume>:<fpage>552</fpage>&#x02013;<lpage>563</lpage>.<pub-id pub-id-type="pmid">24265351</pub-id></mixed-citation></ref><ref id="cam4595-bib-0005"><label>5</label><mixed-citation publication-type="journal">
<string-name>
<surname>Dieci</surname>, <given-names>M. V.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Arnedos</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Andre</surname>
</string-name>, and <string-name>
<given-names>J. C.</given-names>
<surname>Soria</surname>
</string-name>. <year>2013</year>
<article-title>Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives</article-title>. <source>Cancer Discov.</source>
<volume>3</volume>:<fpage>264</fpage>&#x02013;<lpage>279</lpage>.<pub-id pub-id-type="pmid">23418312</pub-id></mixed-citation></ref><ref id="cam4595-bib-0006"><label>6</label><mixed-citation publication-type="journal">
<string-name>
<surname>Di Stefano</surname>, <given-names>A. L.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Fucci</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Frattini</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Labussiere</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Mokhtari</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Zoppoli</surname>
</string-name>, et&#x000a0;al. <year>2015</year>
<article-title>Detection, characterization and inhibition of FGFR&#x02010;TACC fusions in IDH wild type glioma</article-title>. <source>Clin. Cancer Res.</source>
<volume>21</volume>:<fpage>3307</fpage>&#x02013;<lpage>3317</lpage>.<pub-id pub-id-type="pmid">25609060</pub-id></mixed-citation></ref><ref id="cam4595-bib-0007"><label>7</label><mixed-citation publication-type="journal">
<string-name>
<surname>Pulte</surname>, <given-names>D.</given-names>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Brenner</surname>
</string-name>. <year>2010</year>
<article-title>Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis</article-title>. <source>Oncologist</source>
<volume>15</volume>:<fpage>994</fpage>&#x02013;<lpage>1001</lpage>.<pub-id pub-id-type="pmid">20798198</pub-id></mixed-citation></ref><ref id="cam4595-bib-0008"><label>8</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kang</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kiess</surname>
</string-name>, and <string-name>
<given-names>C. H.</given-names>
<surname>Chung</surname>
</string-name>. <year>2015</year>
<article-title>Emerging biomarkers in head and neck cancer in the era of genomics</article-title>. <source>Nat. Rev. Clin. Oncol.</source>
<volume>12</volume>:<fpage>11</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">25403939</pub-id></mixed-citation></ref><ref id="cam4595-bib-0009"><label>9</label><mixed-citation publication-type="book">
<collab collab-type="authors">Nederlandse Vereniging voor KNO</collab>
<year>2014</year>
<article-title>Richtlijn hoofd&#x02010;halstumoren</article-title>.<publisher-loc>Utrecht</publisher-loc>
</mixed-citation></ref><ref id="cam4595-bib-0010"><label>10</label><mixed-citation publication-type="journal">
<string-name>
<surname>van Kempen</surname>, <given-names>P. M.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>van Bockel</surname>
</string-name>, <string-name>
<given-names>W. W.</given-names>
<surname>Braunius</surname>
</string-name>, <string-name>
<given-names>C.&#x000a0;B.</given-names>
<surname>Moelans</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>van Olst</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>de Jong</surname>
</string-name>, et&#x000a0;al. <year>2014</year>
<article-title>HPV&#x02010;positive oropharyngeal squamous cell carcinoma is associated with TIMP3 and CADM1 promoter hypermethylation</article-title>. <source>Cancer Med.</source>
<volume>3</volume>:<fpage>1185</fpage>&#x02013;<lpage>1196</lpage>.<pub-id pub-id-type="pmid">25065733</pub-id></mixed-citation></ref><ref id="cam4595-bib-0011"><label>11</label><mixed-citation publication-type="journal">
<string-name>
<surname>Hughes</surname>, <given-names>S. E.</given-names>
</string-name>
<year>1997</year>
<article-title>Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues</article-title>. <source>J. Histochem. Cytochem.</source>
<volume>45</volume>:<fpage>1005</fpage>&#x02013;<lpage>1019</lpage>.<pub-id pub-id-type="pmid">9212826</pub-id></mixed-citation></ref><ref id="cam4595-bib-0012"><label>12</label><mixed-citation publication-type="book">
<string-name>
<surname>Williams</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<given-names>J. N.</given-names>
<surname>Mandrekar</surname>
</string-name>, <string-name>
<given-names>S. J.</given-names>
<surname>Mandrekar</surname>
</string-name>, <string-name>
<given-names>S.&#x000a0;S.</given-names>&#x000a0;<surname>Cha</surname>
</string-name>, and <string-name>
<given-names>A. F.</given-names>
<surname>Furth</surname>
</string-name>. <year>2006</year>
<source>Finding optimal cutpoints for continuous covariates with binary and time&#x02010;to&#x02010;Event outcomes</source>. <publisher-name>Mayo Foundation</publisher-name>, <publisher-loc>Rochester</publisher-loc>.</mixed-citation></ref><ref id="cam4595-bib-0013"><label>13</label><mixed-citation publication-type="journal">
<string-name>
<surname>Schildhaus</surname>, <given-names>H. U.</given-names>
</string-name>, <string-name>
<given-names>L. C.</given-names>
<surname>Heukamp</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Merkelbach&#x02010;Bruse</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Riesner</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Schmitz</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Binot</surname>
</string-name>, et&#x000a0;al. <year>2012</year>
<article-title>Definition of a fluorescence in&#x02010;situ hybridization score identifies high&#x02010; and low&#x02010;level FGFR1 amplification types in squamous cell lung cancer</article-title>. <source>Mod. Pathol.</source>
<volume>25</volume>:<fpage>1473</fpage>&#x02013;<lpage>1480</lpage>.<pub-id pub-id-type="pmid">22684217</pub-id></mixed-citation></ref><ref id="cam4595-bib-0014"><label>14</label><mixed-citation publication-type="journal">
<string-name>
<surname>Gao</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>B. A.</given-names>
<surname>Aksoy</surname>
</string-name>, <string-name>
<given-names>U.</given-names>
<surname>Dogrusoz</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Dresdner</surname>
</string-name>, <string-name>
<given-names>B.</given-names>&#x000a0;<surname>Gross</surname>
</string-name>, <string-name>
<given-names>S. O.</given-names>
<surname>Sumer</surname>
</string-name>, et&#x000a0;al. <year>2013</year>
<article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title>. <source>Sci. Signal.</source>
<volume>6</volume>:<fpage>p11</fpage>.</mixed-citation></ref><ref id="cam4595-bib-0015"><label>15</label><mixed-citation publication-type="journal">
<string-name>
<surname>Cerami</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Gao</surname>
</string-name>, <string-name>
<given-names>U.</given-names>
<surname>Dogrusoz</surname>
</string-name>, <string-name>
<given-names>B. E.</given-names>
<surname>Gross</surname>
</string-name>, <string-name>
<given-names>S.&#x000a0;O.</given-names>&#x000a0;<surname>Sumer</surname>
</string-name>, <string-name>
<given-names>B. A.</given-names>
<surname>Aksoy</surname>
</string-name>, et&#x000a0;al. <year>2012</year>
<article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title>. <source>Cancer Discov.</source>
<volume>2</volume>:<fpage>401</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">22588877</pub-id></mixed-citation></ref><ref id="cam4595-bib-0016"><label>16</label><mixed-citation publication-type="journal">
<string-name>
<surname>Henson</surname>, <given-names>B. J.</given-names>
</string-name>, and <string-name>
<given-names>S. M.</given-names>
<surname>Gollin</surname>
</string-name>. <year>2010</year>
<article-title>Overexpression of KLF13 and FGFR3 in oral cancer cells</article-title>. <source>Cytogenet. Genome Res.</source>
<volume>128</volume>:<fpage>192</fpage>&#x02013;<lpage>198</lpage>.<pub-id pub-id-type="pmid">20539070</pub-id></mixed-citation></ref><ref id="cam4595-bib-0017"><label>17</label><mixed-citation publication-type="journal">
<string-name>
<surname>Uzawa</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ishigami</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Fushimi</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Kawata</surname>
</string-name>, <string-name>
<given-names>K.</given-names>&#x000a0;<surname>Shinozuka</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Kasamatsu</surname>
</string-name>, et&#x000a0;al. <year>2011</year>
<article-title>Targeting fibroblast growth factor receptor 3 enhances radiosensitivity in human squamous cancer cells</article-title>. <source>Oncogene</source>
<volume>30</volume>:<fpage>4447</fpage>&#x02013;<lpage>4452</lpage>.<pub-id pub-id-type="pmid">21577207</pub-id></mixed-citation></ref><ref id="cam4595-bib-0018"><label>18</label><mixed-citation publication-type="journal">
<string-name>
<surname>Turo</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Harnden</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Thygesen</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Fleischmann</surname>
</string-name>, <string-name>
<given-names>G.&#x000a0;N.</given-names>
<surname>Thalmann</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Seiler</surname>
</string-name>, et&#x000a0;al. <year>2015</year>
<article-title>FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases</article-title>. <source>J. Urol.</source>
<volume>193</volume>:<fpage>325</fpage>&#x02013;s<lpage>330</lpage>.<pub-id pub-id-type="pmid">24933362</pub-id></mixed-citation></ref><ref id="cam4595-bib-0019"><label>19</label><mixed-citation publication-type="journal">
<string-name>
<surname>Guancial</surname>, <given-names>E. A.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Werner</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Bellmunt</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Bamias</surname>
</string-name>, <string-name>
<given-names>T.&#x000a0;K.</given-names>
<surname>Choueiri</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Ross</surname>
</string-name>, et&#x000a0;al. <year>2014</year>
<article-title>FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder</article-title>. <source>Cancer Med.</source>
<volume>3</volume>:<fpage>835</fpage>&#x02013;<lpage>844</lpage>.<pub-id pub-id-type="pmid">24846059</pub-id></mixed-citation></ref><ref id="cam4595-bib-0020"><label>20</label><mixed-citation publication-type="journal">
<string-name>
<surname>G&#x000f3;mez&#x02010;Rom&#x000e1;n</surname>, <given-names>J. J.</given-names>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Saenz</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Molina</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Cuevas Gonz&#x000e1;lez</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Escuredo</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Santa Cruz</surname>
</string-name>, et&#x000a0;al. <year>2005</year>
<article-title>Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth</article-title>. <source>Clin. Cancer Res.</source>
<volume>11</volume>:<fpage>459</fpage>&#x02013;<lpage>465</lpage>.<pub-id pub-id-type="pmid">15701828</pub-id></mixed-citation></ref><ref id="cam4595-bib-0021"><label>21</label><mixed-citation publication-type="journal">
<string-name>
<surname>Tomlinson</surname>, <given-names>D. C.</given-names>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Baldo</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Harnden</surname>
</string-name>, and <string-name>
<given-names>M. A.</given-names>
<surname>Knowles</surname>
</string-name>. <year>2007</year>
<article-title>FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer</article-title>. <source>J. Pathol.</source>
<volume>213</volume>:<fpage>91</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">17668422</pub-id></mixed-citation></ref><ref id="cam4595-bib-0022"><label>22</label><mixed-citation publication-type="journal">
<string-name>
<surname>Qiu</surname>, <given-names>W. H.</given-names>
</string-name>, <string-name>
<given-names>B. S.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>P. G.</given-names>
<surname>Chu</surname>
</string-name>, <string-name>
<given-names>W. G.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>C.</given-names>&#x000a0;<surname>Chung</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Shih</surname>
</string-name>, et&#x000a0;al. <year>2005</year>
<article-title>Over&#x02010;expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma</article-title>. <source>World J. Gastroenterol.</source>
<volume>11</volume>:<fpage>5266</fpage>&#x02013;<lpage>5272</lpage>.<pub-id pub-id-type="pmid">16149130</pub-id></mixed-citation></ref><ref id="cam4595-bib-0023"><label>23</label><mixed-citation publication-type="journal">
<string-name>
<surname>Kuroso</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Imai</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Kobayashi</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Yanagimoto</surname>
</string-name>, <string-name>
<given-names>T.</given-names>&#x000a0;<surname>Suzuki</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Kojima</surname>
</string-name>, et&#x000a0;al. <year>2010</year>
<article-title>Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis</article-title>. <source>Pathobiology</source>
<volume>77</volume>:<fpage>231</fpage>&#x02013;<lpage>240</lpage>.<pub-id pub-id-type="pmid">21116113</pub-id></mixed-citation></ref><ref id="cam4595-bib-0024"><label>24</label><mixed-citation publication-type="journal">
<string-name>
<surname>Chang</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>A. K.</given-names>
<surname>Stewart</surname>
</string-name>, <string-name>
<given-names>X. Y.</given-names>
<surname>Qi</surname>
</string-name>, <string-name>
<given-names>Z. H.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>Q. L.</given-names>
<surname>Yi</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Trudel</surname>
</string-name>. <year>2005</year>
<article-title>Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma</article-title>. <source>Blood</source>
<volume>106</volume>:<fpage>353</fpage>&#x02013;<lpage>355</lpage>.<pub-id pub-id-type="pmid">15761022</pub-id></mixed-citation></ref><ref id="cam4595-bib-0025"><label>25</label><mixed-citation publication-type="journal">
<string-name>
<surname>Mandinova</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Kolev</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Neel</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Hu</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Stonely</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Lieb</surname>
</string-name>, et&#x000a0;al. <year>2009</year>
<article-title>A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans</article-title>. <source>J. Clin. Invest.</source>
<volume>119</volume>:<fpage>3127</fpage>&#x02013;<lpage>3137</lpage>.<pub-id pub-id-type="pmid">19729838</pub-id></mixed-citation></ref><ref id="cam4595-bib-0026"><label>26</label><mixed-citation publication-type="journal">
<string-name>
<surname>Duperret</surname>, <given-names>E. K.</given-names>
</string-name>, <string-name>
<given-names>S. J.</given-names>
<surname>Oh</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>McNeal</surname>
</string-name>, <string-name>
<given-names>S. M.</given-names>
<surname>Prouty</surname>
</string-name>, and <string-name>
<given-names>T. W.</given-names>
<surname>Ridky</surname>
</string-name>. <year>2014</year>
<article-title>Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors</article-title>. <source>Cell Cycle</source>
<volume>13</volume>:<fpage>1551</fpage>&#x02013;<lpage>1559</lpage>.<pub-id pub-id-type="pmid">24626198</pub-id></mixed-citation></ref><ref id="cam4595-bib-0027"><label>27</label><mixed-citation publication-type="journal">
<string-name>
<surname>Ipenburg</surname>, <given-names>N. A.</given-names>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Koole</surname>
</string-name>, <string-name>
<given-names>K. S.</given-names>
<surname>Liem</surname>
</string-name>, <string-name>
<given-names>P. M.</given-names>
<surname>van Kempen</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Koole</surname>
</string-name>, <string-name>
<given-names>P. J.</given-names>
<surname>van Diest</surname>
</string-name>, et&#x000a0;al. <year>2015</year>
<article-title>Fibroblast growth factor receptor family members as prognostic biomarkers in head and neck squamous cell carcinoma</article-title>. <source>Target. Oncol.</source> doi:<ext-link ext-link-type="doi" xlink:href="10.1007/s11523-015-0374-9">10.1007/s11523&#x02010;015&#x02010;0374&#x02010;9</ext-link>.</mixed-citation></ref><ref id="cam4595-bib-0028"><label>28</label><mixed-citation publication-type="journal">
<string-name>
<surname>Woenckhaus</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Merk</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Stoehr</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Schaeper</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Gaumann</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Wiebe</surname>
</string-name>, et&#x000a0;al. <year>2008</year>
<article-title>Prognostic value of FHIT, CTNNB1, and MUC1 expression in non&#x02010;small cell lung cancer</article-title>. <source>Hum. Pathol.</source>
<volume>39</volume>:<fpage>126</fpage>&#x02013;<lpage>136</lpage>.<pub-id pub-id-type="pmid">17949785</pub-id></mixed-citation></ref><ref id="cam4595-bib-0029"><label>29</label><mixed-citation publication-type="journal">
<string-name>
<surname>Mhawech&#x02010;Fauceglia</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>R. T.</given-names>
<surname>Cheney</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Fischer</surname>
</string-name>, <string-name>
<given-names>A.</given-names>&#x000a0;<surname>Beck</surname>
</string-name>, and <string-name>
<given-names>F. R.</given-names>
<surname>Herrmann</surname>
</string-name>. <year>2006</year>
<article-title>FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer</article-title>. <source>Eur. J. Surg. Oncol.</source>
<volume>32</volume>:<fpage>231</fpage>&#x02013;<lpage>237</lpage>.<pub-id pub-id-type="pmid">16412606</pub-id></mixed-citation></ref><ref id="cam4595-bib-0030"><label>30</label><mixed-citation publication-type="journal">
<string-name>
<surname>Maeng</surname>, <given-names>Y. H.</given-names>
</string-name>, <string-name>
<given-names>S. Y.</given-names>
<surname>Eun</surname>
</string-name>, and <string-name>
<given-names>J. S.</given-names>
<surname>Huh</surname>
</string-name>. <year>2010</year>
<article-title>Expression of fibroblast growth factor receptor 3 in the recurrence of non&#x02010;muscle&#x02010;invasive urothelial carcinoma of the bladder</article-title>. <source>Korean J. Urol.</source>
<volume>51</volume>:<fpage>94</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">20414420</pub-id></mixed-citation></ref><ref id="cam4595-bib-0031"><label>31</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bodoor</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ghabkari</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Jaradat</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Alkhateeb</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Jaradat</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Al&#x02010;Ghazo</surname>
</string-name>, et&#x000a0;al. <year>2010</year>
<article-title>FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population</article-title>. <source>Cancer Epidemiol.</source>
<volume>34</volume>:<fpage>724</fpage>&#x02013;<lpage>732</lpage>.<pub-id pub-id-type="pmid">20542753</pub-id></mixed-citation></ref><ref id="cam4595-bib-0032"><label>32</label><mixed-citation publication-type="journal">
<string-name>
<surname>van Rhijn</surname>, <given-names>B. W.</given-names>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>A. N.</given-names>
<surname>Vis</surname>
</string-name>, <string-name>
<given-names>P. J.</given-names>
<surname>Bostrom</surname>
</string-name>, <string-name>
<given-names>T. C.</given-names>&#x000a0;<surname>Zuiverloon</surname>
</string-name>, <string-name>
<given-names>N. E.</given-names>
<surname>Fleshner</surname>
</string-name>, et&#x000a0;al. <year>2012</year>
<article-title>Prognostic value of molecular markers, sub&#x02010;stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer</article-title>. <source>BJU Int.</source>
<volume>110</volume>:<fpage>1169</fpage>&#x02013;<lpage>1176</lpage>.<pub-id pub-id-type="pmid">22448597</pub-id></mixed-citation></ref><ref id="cam4595-bib-0033"><label>33</label><mixed-citation publication-type="journal">
<string-name>
<surname>Sung</surname>, <given-names>J. Y.</given-names>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Sun</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Chang Jeong</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Il Seo</surname>
</string-name>, <string-name>
<given-names>S.</given-names>&#x000a0;<surname>Soo Jeon</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Moo Lee</surname>
</string-name>, et&#x000a0;al. <year>2014</year>
<article-title>FGFR3 overexpression is prognostic of adverse outcome for&#x000a0;muscle&#x02010;invasive bladder carcinoma treated with&#x000a0;adjuvant chemotherapy</article-title>. <source>Urol. Oncol.</source>
<volume>32</volume>:<fpage>49.e23</fpage>&#x02013;<lpage>49.e31</lpage>.<pub-id pub-id-type="pmid">24360661</pub-id></mixed-citation></ref><ref id="cam4595-bib-0034"><label>34</label><mixed-citation publication-type="journal">
<string-name>
<surname>Bertz</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Abe&#x000e9;</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Schwarz&#x02010;Furlan</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Alfer</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Hofst&#x000e4;dter</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Stoehr</surname>
</string-name>, et&#x000a0;al. <year>2014</year>
<article-title>Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer</article-title>. <source>Virchows Arch.</source>
<volume>465</volume>:<fpage>687</fpage>&#x02013;<lpage>695</lpage>.<pub-id pub-id-type="pmid">25326864</pub-id></mixed-citation></ref><ref id="cam4595-bib-0035"><label>35</label><mixed-citation publication-type="journal">
<collab collab-type="authors">Cancer Genome Atlas Network</collab>
<year>2015</year>
<article-title>Comprehensive genomic characterization of head and neck squamous cell carcinomas</article-title>. <source>Nature</source>
<volume>517</volume>:<fpage>576</fpage>&#x02013;<lpage>582</lpage>.<pub-id pub-id-type="pmid">25631445</pub-id></mixed-citation></ref><ref id="cam4595-bib-0036"><label>36</label><mixed-citation publication-type="journal">
<string-name>
<surname>Seiwert</surname>, <given-names>T. Y.</given-names>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Zuo</surname>
</string-name>, <string-name>
<given-names>M. K.</given-names>
<surname>Keck</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Khattri</surname>
</string-name>, <string-name>
<given-names>C. S.</given-names>
<surname>Pedamallu</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Stricker</surname>
</string-name>, et&#x000a0;al. <year>2015</year>
<article-title>Integrative and comparative genomic analysis of HPV&#x02010;positive and HPV&#x02010;negative head and neck squamous cell carcinomas</article-title>. <source>Clin. Cancer Res.</source>
<volume>21</volume>:<fpage>632</fpage>&#x02013;<lpage>641</lpage>.<pub-id pub-id-type="pmid">25056374</pub-id></mixed-citation></ref><ref id="cam4595-bib-0037"><label>37</label><mixed-citation publication-type="journal">
<string-name>
<surname>Hammerman</surname>, <given-names>P. S.</given-names>
</string-name>, <string-name>
<given-names>D. N.</given-names>
<surname>Hayes</surname>
</string-name>, and <string-name>
<given-names>J. R.</given-names>
<surname>Grandis</surname>
</string-name>. <year>2015</year>
<article-title>Therapeutic insights from genomic studies of head and Neck squamous cell carcinomas</article-title>. <source>Cancer Discov.</source>
<volume>5</volume>:<fpage>239</fpage>&#x02013;<lpage>245</lpage>.<pub-id pub-id-type="pmid">25643909</pub-id></mixed-citation></ref></ref-list></back></article>